gptkbp:instance_of
|
gptkb:Antihero
|
gptkbp:approves
|
gptkb:2016
gptkb:FDA
|
gptkbp:atccode
|
N03 AX20
|
gptkbp:available_on
|
gptkb:Software_Solutions
gptkb:tablet
injection
|
gptkbp:brand
|
gptkb:Briviact
|
gptkbp:casnumber
|
357336-20-0
|
gptkbp:category
|
gptkb:unknown
gptkb:C
|
gptkbp:chemical_formula
|
C11 H14 N2 O3
|
gptkbp:class
|
anticonvulsants
|
gptkbp:clinical_trial
|
Phase III
|
gptkbp:clinical_use
|
monotherapy
adjunctive therapy
|
gptkbp:contraindication
|
hypersensitivity
|
gptkbp:defines
|
UCB 34714
|
gptkbp:developed_by
|
gptkb:UCB_Pharma
|
gptkbp:dosage_form
|
oral tablet
oral solution
IV injection
|
gptkbp:duration
|
short-term
long-term
|
gptkbp:excretion
|
urine
|
https://www.w3.org/2000/01/rdf-schema#label
|
Brivaracetam
|
gptkbp:indication
|
partial-onset seizures
|
gptkbp:interacts_with
|
gptkb:beer
oral contraceptives
other antiepileptic drugs
|
gptkbp:lifespan
|
8 to 9 hours
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:Australia
gptkb:Canada
gptkb:Japan
gptkb:United_States
|
gptkbp:mechanism_of_action
|
SV2 A binding
|
gptkbp:metabolism
|
liver
|
gptkbp:pharmacokinetics
|
linear pharmacokinetics
|
gptkbp:research_areas
|
clinical trials
neurology
pharmacology
|
gptkbp:route_of_administration
|
oral
intravenous
|
gptkbp:side_effect
|
dizziness
fatigue
nausea
irritability
drowsiness
|
gptkbp:structure
|
pyrrolidine derivative
|
gptkbp:targets
|
synaptic vesicle protein 2 A
|
gptkbp:used_for
|
gptkb:epilepsy
|
gptkbp:bfsParent
|
gptkb:Briviact
|
gptkbp:bfsLayer
|
7
|